论文部分内容阅读
近年肿瘤标记物不仅对恶性肿瘤诊断、疗效监测、早期发现复发有很重要的作用,而且在对良性疾病的诊断、疗效判定上已为临床所应用。日本于1985年成立妇产科肿瘤标记物研究会,每年举行例会,现已进行5次,对有关妇产科范围肿瘤标记物的种类、频率及其发展进行了整理,肿瘤标记物的研究基础是应用单克隆抗体技术,目前研究最多的是CA125(癌抗原125),其次顺序为CEA(癌胚抗原)、CA19-9(糖链性癌抗原第1号的糖抗原19-9)、TPA(组织多肽抗原)、IAP(免疫抑制酸性蛋白)、TA-4(SCC)(鳞状细胞癌相关抗抗原)、ferritin(铁蛋白)、LDH(乳酸脱氢酶)、SP及
In recent years, tumor markers not only have an important role in the diagnosis of malignant tumors, monitoring of curative effects and early detection of recurrence, but also have clinical application in the diagnosis and curative effect determination of benign diseases. Japan established the Obstetrics and Gynecology Tumor Markers Research Society in 1985 and holds regular meetings each year. It has conducted 5 sessions to sort out the types, frequencies and development of tumor markers in the field of obstetrics and gynecology. The basis for the study of tumor markers Is the application of monoclonal antibody technology, currently the most studied is CA125 (cancer antigen 125), followed by CEA (carcinoembryonic antigen), CA19-9 (sugar chain antigen 1 cancer antigen 19-9), TPA (Tissue polypeptide antigen), IAP (immunosuppressive acidic protein), TA-4 (SCC) (squamous cell carcinoma associated antigens), ferritin, LDH